Intelligence Profile
Clinical Applications
Piclidenoson is an A3 adenosine receptor agonist investigated for various conditions due to its anti-inflammatory and immunomodulatory properties.
Plaque Psoriasis: Piclidenoson has shown promise in treating plaque psoriasis. A systematic review and meta-analysis of randomized controlled trials highlighted its efficacy and safety (PMID: 39549073). The COMFORT-1 phase 3 trial also supported these findings, indicating clinical benefit in managing this skin condition (PMID: 38279575). An upcoming phase 3 trial aims to further assess its efficacy and safety.
Rheumatoid Arthritis: In a completed phase 2 trial (NCT01034306), piclidenoson was evaluated for rheumatoid arthritis, demonstrating potential therapeutic benefits.
Canine Osteoarthritis: A pilot study in veterinary science found clinical benefits of piclidenoson in managing canine osteoarthritis, suggesting its broader anti-inflammatory potential (PMID: 42339095).
Keratoconjunctivitis Sicca (Dry Eye Syndrome): A completed phase 2 trial (NCT00349466) explored its use for dry eye syndrome, indicating possible advantages in treating this condition.
COVID-19: Although piclidenoson was investigated during a phase 2 trial for COVID-19 treatment (NCT04333472), more data are needed to determine its role in viral infection management.
Potential Conditions Under Investigation: Future research includes studies on Lowe Syndrome and further exploration in plaque psoriasis, with trials not yet recruiting (NCT07410455, NCT06643260).
Overall, while the current evidence supports various applications of piclidenoson, ongoing and future trials will provide more precise conclusions on its efficacy and safety across different conditions.
Disclaimer: This content is for informational purposes and is not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.